diffuse large B cell lymphoma
Conditions
Interventions
Six cycles of R-miniCHP are scheduled as an induction therapy.
Sponsors
Clinical Hematology Study Group of National Hospital Organization(CHSG-NHO)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.pathological diagnosis: diffuse large B cell lymphoma, NOS 2.CD20 antigen positive 3.CSI bulky, CSII/III/IV 4.presence of mesurable lesions 5.no prior therapy for lymphoma except pre-treatment with PSL 6.age: more than 80 years old 7.PS(ECOG): 0-2 (even after pre-treatment with PSL) 8.adequate organ funcitions 9.informed consented patients
Exclusion criteria
Exclusion criteria: 1.presence of active infeciton 2.presence of central nervous invasion 3.past history of glaucoma. 4.past history of severe drug allergy. 5.HIV Ab positive or HTLV-1 Ab positive. 6.HBsAg positive or HCV Ab positive. 7.severe cardiac disease 8.hepatic cirrhosis 9.uncontrollable diabetis melitus 10.patients with dialysis 11.lung fibrosis or interstitial pneumonitis 12.other active malignancies 13.pregnant or feeding female 14.severe mental disorder 15.continuous systemic administration of steroid 16.judged for inappropriate with other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year over all survival, (complete) remission rate, safety, incidence of febrile neutropenia | — |
Countries
Japan
Contacts
Public ContactYasuhiko Miyata
National Hospital Organization Nagoya Medical Center Department of Hematology
Outcome results
None listed